Literature DB >> 1317261

Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.

M Hermanson1, K Funa, M Hartman, L Claesson-Welsh, C H Heldin, B Westermark, M Nistér.   

Abstract

The expression of platelet-derived growth factor (PDGF) and its receptors was analyzed in 14 gliomas of various degrees of malignancy and compared with three gliosis cases by in situ hybridization and immunohistochemistry techniques. Expression of both PDGF A- and B-chains was higher in glioblastomas than in astrocytomas. The PDGF A-chain mRNA was predominantly found in cell-rich areas in glioblastomas. The cognate PDGF-alpha receptor (PDGFR-alpha) mRNA was heterogeneously distributed in gliomas of all grades, and PDGFR-alpha expression was higher in gliomas than in gliosis. Within some glioblastomas probed with PDGFR-alpha complementary RNA, cells heavily loaded with grains were intermingled with others containing low or moderate signals. The heavily labeled cells were often found in the vicinity of proliferating capillaries. Immunostaining with an anti-PDGF antibody and an affinity-purified antiserum against the PDGFR-alpha showed strong staining of most tumor cells with both antibodies in glioblastoma. In addition, the PDGFR-alpha antibodies yielded a strong staining of scattered cells, and the anti-PDGF antibody yielded staining of a few cells within the astrocytoma. Furthermore, high levels of the PDGF-beta receptor (PDGFR-beta) and PDGF B-chain mRNA as well as the beta receptor protein were found in hyperplastic capillaries. These results suggest the presence of autocrine and paracrine loops in glioma, activating the PDGFR-alpha in glioma cells and the PDGFR-beta in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317261

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  208 in total

1.  Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Authors:  Youngmi Kim; Eunhee Kim; Qiulian Wu; Olga Guryanova; Masahiro Hitomi; Justin D Lathia; David Serwanski; Andrew E Sloan; Robert J Weil; Jeongwu Lee; Akiko Nishiyama; Shideng Bao; Anita B Hjelmeland; Jeremy N Rich
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.

Authors:  Mukul Minocha; Varun Khurana; Bin Qin; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2012-06-09       Impact factor: 5.875

3.  Autocrine platelet-derived growth factor-vascular endothelial growth factor receptor-related (Pvr) pathway activity controls intestinal stem cell proliferation in the adult Drosophila midgut.

Authors:  David Bond; Edan Foley
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

4.  Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.

Authors:  Alisa Madalina Popescu; Oana Alexandru; Corina Brindusa; Stefana Oana Purcaru; Daniela Elise Tache; Ligia Gabriela Tataranu; Citto Taisescu; Anica Dricu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

5.  FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells.

Authors:  Ai-Hua Gong; Ping Wei; Sicong Zhang; Jun Yao; Ying Yuan; Ai-Dong Zhou; Frederick F Lang; Amy B Heimberger; Ganesh Rao; Suyun Huang
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

6.  Cellular components of microvascular proliferation in human glial and metastatic brain neoplasms. A light microscopic and immunohistochemical study of formalin-fixed, routinely processed material.

Authors:  P Wesseling; J J Vandersteenhoven; B T Downey; D J Ruiter; P C Burger
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

7.  Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Elizabeth R Gerstner; Xiaobu Ye; Serena Desideri; Daniel G Duda; David Peereboom; Glenn J Lesser; Sajeel Chowdhary; Patrick Y Wen; Stuart Grossman; Jeffrey G Supko
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

8.  Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma.

Authors:  R A Segal; L C Goumnerova; Y K Kwon; C D Stiles; S L Pomeroy
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

9.  Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

Authors:  E Buchdunger; J Zimmermann; H Mett; T Meyer; M Müller; U Regenass; N B Lydon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.